Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
about
CARs on a highway with roadblocks.The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.Safety strategies of genetically engineered T cells in cancer immunotherapy.Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.Cytokine Release Syndrome Grade is a Predictive Marker for Infections in Relapsed or Refractory B-cell All Patients Treated with CAR T Cells.T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report.Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.The Pharmacology of T Cell Therapies.Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.Cytokine release syndrome.Immunotherapy for Gastric Cancer: Time for a Personalized Approach?Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell TherapyNephrotoxicity of Cancer Immunotherapies: Past, Present and FutureImmune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T CellsA Growing Problem of Critical Illness Due to Chimeric Antigen Receptor T-Cell TherapyTrial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementCytokine release syndrome: grading, modeling, and new therapyThe biological basis and clinical symptoms of CAR-T therapy-associated toxicitesA carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapyRecombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancyHemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy
P2860
Q45875485-8C6CA502-BD34-4C21-8E42-DD4FB2500E66Q47114749-06E85260-A070-4CE2-A918-F89EE02877A3Q47285613-A22CC3FC-3C45-4ED8-9776-29B97E726FDFQ47443955-0B8AA968-0151-436B-9206-3CA15CB1E2DCQ47667620-0D9F1F18-469A-4F25-A421-322D5CA55831Q47718243-BB0DD302-691E-48DE-BF62-9CDC60270192Q49878390-AB18F084-05B8-4A67-90D6-DB2A76279BBDQ50531950-34D08C1C-6ADE-4471-ABC2-31365D4BDBB6Q52645931-C3686A8F-71C2-4E0E-8C39-F8EC94CDA74AQ52663662-99135BE9-980B-4F11-AF10-1735BEC9596FQ52685045-DD9D0292-6B7B-4238-943D-F672426C1533Q52689465-A1EC08E2-BB32-4989-A9E3-2A3E7E6B4E0EQ52729230-AFE66106-BAB5-4493-B5E4-7FD77597181EQ54233295-FD7689A2-6DFD-4E0F-8CFC-890E67355894Q54967775-62BC7809-70CE-4E65-81E2-094CE961F2DCQ54985631-A07DC052-3E28-4E1A-A4C2-DEF754787B9BQ55292778-BD4DC8CE-1696-4981-83B5-D04CA60E4730Q55340132-6F4613C8-F912-4CE0-9676-EC8E40EE45D5Q55438228-129A1F37-78D4-4C0A-9B71-058340ACBAC2Q55652343-4629CC11-CC47-4FF5-94AA-47128A9A875BQ56333808-8A97B529-0D49-4043-BA24-1326046CE585Q57172529-4D3B8F08-1F2C-4320-AA92-75776505FE8AQ57173949-90AEA5A6-EE75-4466-BBD0-B04B5B710C79Q57455390-48CDF0FA-6919-4D25-BC9E-A3C1F8D87C17Q57810588-53DC3570-391B-4EF9-85F0-ADC27627A6E5Q58700983-2D0F6E09-6FCB-41CE-9463-32914CDED7A2Q58765358-EFCE504F-F957-4B51-9336-FE709212B5BAQ58782542-DD6363EA-6CC4-4925-8DB1-2CE0E710DC8AQ58786421-13ADA865-17C0-4352-91A3-635F8A45B83BQ59126338-22A9E369-48F4-4DC9-BA1C-5D13769FC51D
P2860
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
@en
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
@nl
type
label
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
@en
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
@nl
prefLabel
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
@en
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
@nl
P2093
P2860
P1476
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
@en
P2093
Alison M Gulbis
Cristina Gutierrez
Elizabeth J Shpall
Frederick L Locke
Jason Westin
John F de Groot
Katayoun Rezvani
Krishna V Komanduri
Monica E Loghin
Naval Daver
P2860
P356
10.1038/NRCLINONC.2017.148
P407
P577
2017-09-19T00:00:00Z